Work

FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels

Year: 2019

Type: article

Source: Nature Nanotechnology

DOI: 10.1038/s41565-019-0406-1

Authors: Vicenta Trujillo-Alonso, Edwin C. Pratt, Hongliang Zong, Andres Lara-Martinez, Charalambos Kaittanis, Mohamed O. Rabie, Valerie Longo, Michael W. Becker, Gail J. Roboz, Jan Grimm, Monica L. Guzman

Institutions: Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, Cornell University, University of Rochester Medicine

Language: English

Topic: Iron Metabolism and Disorders

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: University of Rochester, National Institutes of Health, National Cancer Institute

Awards: G1438232664, Biomarkers for predicting response to Hsp90 therapy, Exploiting ferroportin for cancer imaging and therapy, Pharmacological modulation of epigenetic changes in AML, G7807891749, Cancer Center Support Grant

OpenAlex ID: W2924151995

FWCI: 24.1

Cites: 34

Cited by: 321

Related to: 10